Pivotal phase III trial of RP 5063 in patients with schizophrenia.

Trial Profile

Pivotal phase III trial of RP 5063 in patients with schizophrenia.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2013

At a glance

  • Drugs RP 5063 (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Reviva Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2013 Study title is not official. MR 9155878 refers to multiple pivotal phase III trials, but there is no way of distinguishing them. Disease assumed.
    • 06 Nov 2013 New trial record
    • 05 Nov 2013 Initiation of pivotal phase III trials is planned for early 2014, according to a Reviva Pharmaceuticals media release. The company has received guidance from the FDA for the phase III development plan of RP 5063.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top